Kymera Therapeutics (KYMR) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Kymera Therapeutics (NASDAQ: KYMR):

• 9/23/2026 – Kymera Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $140.00 price target on the stock.
• 9/22/2026 – Kymera Therapeutics had its price target raised by Stifel Nicolaus from $132.00 to $152.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Kymera Therapeutics had its price target raised by Bank of America Corporation from $123.00 to $144.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Kymera Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $180.00 price target on the stock.
• 8/31/2026 – Kymera Therapeutics had its price target raised by Guggenheim from $135.00 to $170.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Kymera Therapeutics had its price target raised by Wells Fargo & Company from $116.00 to $151.00. They now have an “overweight” rating on the stock.
• 8/24/2026 – Kymera Therapeutics was upgraded by TD Cowen to “strong-buy”.
• 8/6/2026 – Kymera Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $135.00 price target on the stock.
• 8/6/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 8/6/2026 – Kymera Therapeutics had its price target raised by Barclays PLC from $133.00 to $139.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Kymera Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $125.00 price target on the stock.
• 7/30/2026 – Kymera Therapeutics is now covered by Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $120.00 price target on the stock.
• 7/28/2026 – Kymera Therapeutics had its price target raised by Guggenheim from $125.00 to $135.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, insider Brian Adams sold 6,371 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the sale, the insider directly owned 50,254 shares of the company’s stock, valued at $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the completion of the transaction, the director owned 240,123 shares in the company, valued at $25,573,099.50. This represents a 86.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,392,055 shares of company stock worth $258,718,499 in the last 90 days. Company insiders own 15.98% of the company’s stock.

Kymera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach is based on targeted protein degradation, which uses small-molecule degraders to direct unwanted proteins to the cell’s natural disposal system rather than simply blocking their activity.

Kymera’s research and development activities are supported by its proprietary Pegasus platform, which is designed to identify degradable proteins and create drug candidates against them.